Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases (TKI-CPK)

March 12, 2026 updated by: Centre Oscar Lambret

National Study of Prevalence of Creatinine Phosphokinase (CPK) Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases (TKI)

This study describes the elevation of CPK in patient treated for solid tumors by TKI

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

154

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Angers, France, 49000
        • Centre Paul Papin
      • Besançon, France, 25030
        • Hôpital Jean Minjoz
      • Bordeaux, France, 33076
        • Institut Bergonie
      • Bordeaux, France, 33076
        • CHU Bordeaux
      • Caen, France, 14076
        • Centre Francois Baclesse
      • Clermont-Ferrand, France, 63011
        • Centre Jean Perrin
      • Créteil, France, 94010
        • Hôpital Henri Mondor - APHP
      • Lille, France, 59020
        • Centre Oscar Lambret
      • Limoges, France, 87042
        • CHU Limoges
      • Lyon, France, 69008
        • Centre Leon Berard
      • Lyon, France, 69003
        • Hôpital Edouard Herriot
      • Marseille, France, 13273
        • Institut Paoli Calmettes
      • Montpellier, France, 34298
        • Centre Val d'Aurelle
      • Nice, France, 06189
        • Centre Antoine Lacassagne
      • Paris, France, 75248
        • Institut Curie
      • Paris, France, 75014
        • Hopital Cochin - APHP
      • Paris, France, 75010
        • Hôpital Saint-Louis - APHP
      • Paris, France, 75020
        • Hôpital Tenon - APHP
      • Reims, France, 51056
        • Institut Jean Godinot
      • Reims, France, 51092
        • CHU Robert Debré
      • Rennes, France, 35042
        • Centre Eugène Marquis
      • Rouen, France, 76000
        • Centre Henri Becquerel
      • Saint-Cloud, France, 92211
        • Centre Rene Huguenin
      • Saint-Priest-en-Jarez, France, 42271
        • Institut de Cancerologie de La Loire
      • Toulouse, France, 31052
        • Institut Claudius Regaud
      • Vandœuvre-lès-Nancy, France, 54511
        • Centre Alexis Vautrin
      • Villejuif, France, 94805
        • Institut Gustave Roussy

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients treated for a solid tumor by thyrosin kinase inhibitors

Description

Inclusion Criteria:

  • Patients with solid tumor treated by inhibitor of tyrosin kinase for at least 1 week
  • Patient examined AND with a routine blood test planned
  • Patient informed of procedure for the study who was not opposed to it

Exclusion Criteria:

  • Patient treated for malignant hemopathy
  • Patient no treated by inhibitor of thyrosine kinase or for less than 1 week
  • Patients with no routine blood laboratory tests planned

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patient treated by TKI
Any patient with solid tumor and treated by Thyrosine Kinase Inhibitor for at least 1 week
Biological: CPK dosage
CPK dosage during a blood sample realized at least one week after the begining of the treatment
Other: Clinical exam
Examination of the patient for myalgia, cramps, medical history and concomitant medication

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To evaluate the prevalence of the CPK increase
Time Frame: Within 3 days after a clinical exam
Dosage of CPK during standard blood sampling. The increase of CPK is defined when CPK value > USL
Within 3 days after a clinical exam

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation myalgia/CPK increase
Time Frame: During the clinical exam
To determine the correlation between myalgia and CPK blood, taking into account the risk factors leading to CPK increase
During the clinical exam

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Oscar Lambret

Investigators

  • Principal Investigator: Antoine ADENIS, MD, PhD, Centre Oscar Lambret

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2010

Primary Completion (Actual)

December 1, 2010

Study Completion (Actual)

January 15, 2013

Study Registration Dates

First Submitted

November 24, 2010

First Submitted That Met QC Criteria

November 24, 2010

First Posted (Estimated)

November 25, 2010

Study Record Updates

Last Update Posted (Actual)

March 16, 2026

Last Update Submitted That Met QC Criteria

March 12, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TKI-CPK-1003

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Clinical Trials on CPK dosage

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe